Lycia Therapeutics Inc.

LYCA

NASDAQHealthcareBiotechnology

在 GoAI 中打開

前收盤價

US$30.00

+US$12.00 · +66.67%

10月23日下午4:00 ET

公司概況

公司網站

Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Aetna Wun Trombley
上市以來: 2026年10月23日
僱員: 65

市場位置

日內區間

目前US$30.00

US$22.19US$36.275

52週區間

目前US$30.00

US$22.19US$36.4931

開盤價: US$28.55
前收盤價: US$18.00
成交量: 228.06萬; 1× 平均值
平均成交量: 228.72萬; 日均成交量
市值: 15.63億 USD
貝塔: 0; 市場參考 1
50天平均值: US$30.00; 處於平均水準
200天平均值: US$30.00; 處於平均水準

LYCA 訊息

barrons.com2026年10月24日

Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere

As investors wait for the Claude developer to file its official IPO paperwork, several biotechs are going public and doing just fine.

閱讀原始碼

seekingalpha.com2026年10月24日

U.S. IPO Weekly Recap: Trickle Of Biotech Activity Continues Amid Tech Sell-Off

One biotech IPO debuted this week, while four IPOs submitted initial filings, including two sizable biotech filings. One IPO is currently scheduled for the week ahead as investors continue to hold their breath for the…

閱讀原始碼

globenewswire.com2026年10月22日

Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics…

閱讀原始碼